Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early rebleeding increases mortality of variecal bleeders on secondary prophylaxis with β-blockers and ligation.
Ardevol A, Alvarado-Tapias E, Garcia-Guix M, Brujats A, Gonzalez L, Hernández-Gea V, Aracil C, Pavel O, Cuyas B, Graupera I, Colomo A, Poca M, Torras X, Concepción M, Villanueva C. Ardevol A, et al. Among authors: brujats a. Dig Liver Dis. 2020 Sep;52(9):1017-1025. doi: 10.1016/j.dld.2020.06.005. Epub 2020 Jul 8. Dig Liver Dis. 2020. PMID: 32653417
Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis.
Alvarado-Tapias E, Ardevol A, Garcia-Guix M, Montañés R, Pavel O, Cuyas B, Graupera I, Brujats A, Vilades D, Colomo A, Poca M, Torras X, Guarner C, Concepción M, Aracil C, Torres F, Villanueva C. Alvarado-Tapias E, et al. Among authors: brujats a. J Hepatol. 2020 Oct;73(4):829-841. doi: 10.1016/j.jhep.2020.03.048. Epub 2020 Apr 13. J Hepatol. 2020. PMID: 32298768
Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis.
Villanueva C, Albillos A, Genescà J, Garcia-Pagan JC, Brujats A, Calleja JL, Aracil C, Bañares R, Morillas RM, Poca M, Peñas B, Augustin S, Abraldes JG, Alvarado E, Torres F, Bosch J; PreDesCI Study Investigators. Villanueva C, et al. Among authors: brujats a. J Hepatol. 2021 Sep;75(3):589-599. doi: 10.1016/j.jhep.2021.04.022. Epub 2021 Apr 24. J Hepatol. 2021. PMID: 33905794 Clinical Trial.
Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.
Villanueva C, Torres F, Sarin SK, Shah HA, Tripathi D, Brujats A, Rodrigues SG, Bhardwaj A, Azam Z, Hayes PC, Jindal A, Abid S, Alvarado E, Bosch J; Carvedilol-IPD-MA-group and the Baveno Cooperation: an EASL Consortium. Villanueva C, et al. Among authors: brujats a. J Hepatol. 2022 Oct;77(4):1014-1025. doi: 10.1016/j.jhep.2022.05.021. Epub 2022 May 31. J Hepatol. 2022. PMID: 35661713 Free article.
Predictors of the need for necrosectomy in patients with walled-off pancreatic necrosis treated with lumen apposition metal stents.
González-González L, Bazaga S, Murzi M, Brujats A, Trias M, de Riba B, Romito R, Colán-Hernández J, Concepción M, Gordillo J, Pernas JC, Poca M, Soriano G, Guarner-Argente C. González-González L, et al. Among authors: brujats a. Surg Endosc. 2022 Feb;36(2):1339-1346. doi: 10.1007/s00464-021-08411-3. Epub 2021 Mar 3. Surg Endosc. 2022. PMID: 33660124
Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis.
Reiniš J, Petrenko O, Simbrunner B, Hofer BS, Schepis F, Scoppettuolo M, Saltini D, Indulti F, Guasconi T, Albillos A, Téllez L, Villanueva C, Brujats A, Garcia-Pagan JC, Perez-Campuzano V, Hernández-Gea V, Rautou PE, Moga L, Vanwolleghem T, Kwanten WJ, Francque S, Trebicka J, Gu W, Ferstl PG, Gluud LL, Bendtsen F, Møller S, Kubicek S, Mandorfer M, Reiberger T. Reiniš J, et al. Among authors: brujats a. J Hepatol. 2023 Feb;78(2):390-400. doi: 10.1016/j.jhep.2022.09.012. Epub 2022 Sep 22. J Hepatol. 2023. PMID: 36152767 Free article.
Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to β-blockers: A double-blind, placebo-controlled, randomized-trial.
Alvarado-Tapias E, Brujats A, Puente A, Ardevol A, Rodriguez-Arias A, Fajardo J, Pavel O, Garcia-Guix M, Aracil C, Poca M, Cuyàs B, Cantó E, Montañés R, Garcia-Osuna A, Escorsell À, Torras X, Villanueva C. Alvarado-Tapias E, et al. Among authors: brujats a. Hepatology. 2024 Nov 7. doi: 10.1097/HEP.0000000000001148. Online ahead of print. Hepatology. 2024. PMID: 39509369
Exploring algorithms to select candidates for non-selective beta-blockers in cirrhosis: A post hoc analysis of the PREDESCI trial.
Dajti E, Villanueva C, Berzigotti A, Brujats A, Albillos A, Genescà J, García-Pagán JC, Colecchia A, Bosch J; PREDESCI trial investigators; A study by the Baveno Cooperation, an EASL Consortium. Dajti E, et al. Among authors: brujats a. J Hepatol. 2024 Sep 19:S0168-8278(24)02553-4. doi: 10.1016/j.jhep.2024.09.014. Online ahead of print. J Hepatol. 2024. PMID: 39303875 Free article.
15 results